Excited to share our experience with Impella in managing patients presenting with a post-MI VSR. Study highlights new insights in device use, hemodynamic benefits and improved outcomes within the scope of a shifting treatment paradigm. #jtcvs
https://t.co/6YWCn8UcfP
Safe and effective mobilization of patients with cardiogenic shock receiving tMCS can be accomplished. Appropriate patient selection, tailored device management, and dynamic multidisciplinary approaches to mobilization are critical to success. #cardiogenicshock
In our new review, we discuss considerations for patient-specific device tailoring in temporary mechanical circulatory support for cardiogenic shock, along with strategies to facilitate safe mobilization in appropriately selected patients. @AaronWeissMD
https://t.co/PpQFw1G7Et
Longitudinal follow-up in the largest single-centre Heartmate 3 cohort to date characterizing the nuanced temporal patterns in risks of mortality and adverse events. #lvad#hm3#heartfailure
In 431 HM3 pts @CleClinicHVTI, long-term survival was favorable despite high acuity. Time-varying risks—early neuro events; later infections, GI bleeding, RHF—and rehospitalizations are areas for future improvement strategies. 🔗 https://t.co/TC3zbhuh5n
Stratifying patients in shock receiving Impella 5.5 may help us understand future trajectories. However, even later stages of shock demonstrate acceptable outcomes in appropriately selected patients. Great job @JLmaigrot
Our experience @CleClinicHVTI shows that preop SCAI stage in patients w/ Impella 5.5 is associated w/ survival on support & successful transition to LVAD/transplant. Preop triage may improve risk-benefit assessment and exit-strategy planning. https://t.co/TVm6U8z2cE
Excited to share our experience with Impella in managing patients presenting with a post-MI VSR. Study highlights new insights in device use, hemodynamic benefits and improved outcomes within the scope of a shifting treatment paradigm. #jtcvs
https://t.co/6YWCn8UcfP
It’s an honor to be recognized as the #1 hospital for heart care for the 30th consecutive year.
This is a testament to the commitment, talent and compassion of our @CleClinicHVTI team.
They’re dedicated to excellence in every aspect of their work.
https://t.co/ypmGsORd5i
Can we automate & contextualize literature reviews in #CTSurgery?
Dr. @karamlou et al @ClevelandClinic@IBM@SyracuseU introduce #SciScribe, which promises to save us all hundreds of hours spent on PubMed, Covidence, & other software to search, retrieve, collate info.
#AATS2024
Presenting now and newly published in #JTCVS: Efficacy and Safety of a Transaortic Approach to Midventricular and Apical Septal Myectomy. Maigrot, Smedira, et al. https://t.co/IIUukrDoRN #AATS2024@AaronWeissMD@David_Moros17
Read our article published simultaneously today in #JTCVS.
Fantastic work led by the all-start med student @JLmaigrot
🔗Link: https://t.co/fy9EfVmcCb
@AaronWeissMD#AATS2024@AATSED@AATSHQ
Another fabulous presentation by @CleClinicHVTI research fellow Dr David Moros who argues for a paradigm shift in treating post MI VSRs with Impellas to facilitate non-emergency surgery. Wonderful job David on a tough topic. #AATS2024@AATSHQ@ClevelandClinic@LarsSvenssonMD